Education
About Us
Working with TipRanks
Follow Us
Molecular Partners AG (MLLCF)
OTHER OTC:MLLCF
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 25, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.44Last Year’s EPS
-0.45Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 25, 2025
Earnings Call Sentiment|Positive
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.Successful Execution of 2024 Program Goals
Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.
Positive Financial Health
The company ended 2024 with a cash balance of CHF 149 million, which supports operations into 2027. They raised CHF 20 million through financing, maintaining a solid financial base with no debt.
Encouraging Clinical Results and Pipeline Progression
The T cell engager 533 showed significant improvements in efficacy with new dosing strategies, resulting in 3 complete responses out of 8 patients treated past day 12.
---
MLLCF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MLLCF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $4.62 | $4.62 | 0.00% |
| Aug 26, 2024 | $5.89 | $5.89 | 0.00% |
| Mar 14, 2024 | $4.10 | $4.10 | 0.00% |
| Aug 24, 2023 | $5.90 | $5.90 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Molecular Partners AG (MLLCF) report earnings?
Molecular Partners AG (MLLCF) is schdueled to report earning on Aug 25, 2025, TBA Not Confirmed.
What is Molecular Partners AG (MLLCF) earnings time?
Molecular Partners AG (MLLCF) earnings time is at Aug 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLLCF EPS forecast?
MLLCF EPS forecast for the fiscal quarter 2025 (Q2) is -0.44.
---